Reports Q1 revenue $11.9B, consensus $11.46B. “We had a good start to 2024, with revenue growth, important advances in our pipeline and the closure of several strategically important transactions. Our focus remains on strengthening the company’s long-term growth profile. As a part of our continued evolution, we’re executing a strategic productivity initiative that will allow us to be more agile, drive efficiency across the company, and prioritize investing in opportunities where we see the greatest potential to get the most promising medicines to patients as quickly as possible,” said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. “
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- BMY Earnings this Week: How Will it Perform?
- Bristol Myers price target lowered to $52 from $55 at Cantor Fitzgerald
- Bristol Myers and Cellares sign $380M agreement for CAR T cell therapies
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
- Bristol Myers price target raised to $52 from $51 at Wells Fargo
